C07K 16/3092
Against tumour-associated mucins
Official title: {against tumour-associated mucins}
C07K16/3092 (Against tumour-associated mucins) appears on 383 US grants and 711 published applications in this corpus.
Search patents in C07K- Granted patents
- 383
- Published applications
- 711
- Assignees
- 272
- Inventors
- 1,091
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 6 | 6 |
| 2004 | 0 | 4 |
| 2005 | 0 | 8 |
| 2006 | 3 | 9 |
| 2007 | 4 | 8 |
| 2008 | 2 | 14 |
| 2009 | 4 | 14 |
| 2010 | 10 | 16 |
| 2011 | 7 | 15 |
| 2012 | 8 | 22 |
| 2013 | 15 | 24 |
| 2014 | 19 | 35 |
| 2015 | 26 | 42 |
| 2016 | 39 | 40 |
| 2017 | 21 | 46 |
| 2018 | 17 | 37 |
| 2019 | 25 | 40 |
| 2020 | 23 | 52 |
| 2021 | 31 | 55 |
| 2022 | 25 | 45 |
| 2023 | 19 | 47 |
| 2024 | 30 | 41 |
| 2025 | 27 | 54 |
| 2026 | 21 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-MUC1-C antibodies and CAR-T structures15 Sep 2026US 12,735,503 B2TeneoBio, Inc.
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- PSG1 for use in the treatment of osteoarthritis4 Aug 2026US 12,697,370 B2University College Cork, National University of Ireland, Cork
- Anti-MUC1 compositions and methods of use21 Jul 2026US 12,686,726 B2Poseida Therapeutics, Inc.
- Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof30 Jun 2026US 12,668,632 B2Regeneron Pharmaceuticals, Inc.
- Antibodies and uses thereof1 Oct 2026US 2026/0297188 A1LTZ Therapeutics Inc.
- Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof24 Sep 2026US 2026/0285982 A1Regeneron Pharmaceuticals, Inc.
- Lysine-free ubiquibody variants for long-lived intracellular protein silencing27 Aug 2026US 2026/0250647 A1
- Therapeutic method for low-drug-sensitivity cancers by administration of anti-muc1 antibody-drug conjugate20 Aug 2026US 2026/0241026 A1Daiichi Sankyo Company, Limited
- Anti-muc17, anti-cd3 and anti-cd28 trispecific antibody20 Aug 2026US 2026/0242510 A1Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Most cited
By later US patents
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage541US 5,885,793 ACambridge Antibody Technology Limited · 1999
- Production of anti-self bodies from antibody segment repertories and displayed on phage229US 6,582,915 B1Cambridge Antibody Technology Limited · 2003
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage228US 6,593,081 B1Cambridge Antibody Technology Limited · 2003
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage216US 6,521,404 B1Cambridge Antibody Technology Limited · 2003
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage202US 6,555,313 B1Cambridge Antibody Technology Limited · 2003